SCHEMBL2835102

SCHEMBL2835102

C=CCCCOC(=O)c1cccc(F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.46
TDP1 Q9NUW8 3/20 0.46
BCHE P06276 2/20 0.46
ADRB2 P07550 1/20 0.45
ADRB1 P08588 1/20 0.45
ADRB3 P13945 1/20 0.45
RAB9A P51151 1/20 0.45
CES2 O00748 1/20 0.45
CES1 P23141 1/20 0.45
KMT2A Q03164 1/20 0.44
PTPN2 P17706 1/20 0.44
PTPN1 P18031 1/20 0.44
PTPN6 P29350 1/20 0.44
PTPN11 Q06124 1/20 0.44
ESR1 P03372 1/20 0.43
ESR2 Q92731 1/20 0.43
GPR52 Q9Y2T5 1/20 0.43
PAX8 Q06710 1/20 0.43
PKM P14618 1/20 0.43
PARP1 P09874 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2834471 0.91 CES2 (0.47) NPC1TDP1BCHEADRB2ADRB1
SCHEMBL2705485 0.90 TDP1 (0.53) NPC1TDP1RAB9AALDH1A1L3MBTL1
SCHEMBL2707155 0.85 TDP1 (0.56) NPC1TDP1RAB9AALDH1A1L3MBTL1
SCHEMBL2831834 0.82 CYP3A4 (0.53) NPC1TDP1ADRB2ADRB1ADRB3
SCHEMBL2831218 0.82 ALDH1A1 (0.50) NPC1TDP1ADRB2ADRB1ADRB3
SCHEMBL9844077 0.82 TDP1 (0.70) NPC1TDP1RAB9AKMT2AESR1
SCHEMBL2833609 0.81 KMT2A (0.48) NPC1TDP1RAB9ACES2CES1
SCHEMBL8759408 0.81 L3MBTL1 (0.56) NPC1TDP1RAB9AKMT2AESR1
SCHEMBL11354226 0.80 CES2 (0.52) NPC1TDP1BCHEADRB2ADRB1
SCHEMBL2705499 0.80 ALDH1A1 (0.57) NPC1TDP1RAB9AESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263268-B2 Ester compound, and non-aqueous electrolyte solution and lithium secondary battery each using the ester compound UBE INDUSTRIES, LTD. (JP) 2012-09-11 US disclosed
EP-2108640-B1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES (JP) 2012-07-25 EP disclosed
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES, LTD. (JP) 2010-05-13 US disclosed
EP-2108640-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND Ube Industries, Ltd. (JP) 2009-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND CEL, LAGE3, PEF1 NPC1 962/4885TDP1 3303/4885BCHE 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.